BioPharmSignal logoBioPharmSignal

Biotech News

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Corcept (CORT)CorceptClinical readout

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Apr. 21, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

Open original release

Related news

CORTCorcept2026-04-10 20:45 EST

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

CORTCorcept2026-04-30 20:05 EST

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

VKTXViking Therapeutics2026-05-12 11:05 EST

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

VKTXViking Therapeutics2026-03-26 11:05 EST

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

CRNXCrinetics Pharmaceuticals2026-01-04 21:00 EST

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

NBIXNeurocrine Biosciences2026-05-04 11:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

CRNXCrinetics Pharmaceuticals2026-01-22 21:05 EST

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

NBIXNeurocrine Biosciences2026-05-01 20:05 EST

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

View all latest news

Corcept

Corcept Therapeutics is a biotechnology company focused on cortisol modulation and endocrine disease, with a commercial franchise in Cushing’s syndrome and additional pipeline opportunities. Its business combines specialty commercialization with clinical development.

Recent company news

CORTCorcept2026-05-29 20:33 EST

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

CORTCorcept2026-05-27 12:00 EST

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-04-30 20:05 EST

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

CORTCorcept2026-04-30 20:05 EST

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-04-23 20:05 EST

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Stock data

Close
91.12 USD
Market cap
7.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States